What Bio-Sourcing does

Bio-Sourcing is a Belgian biotechnology company founded in 2014 and headquartered in Liège that has developed the BioMilk platform—a proprietary system using transgenic goats as 'natural bioreactors' to produce fully human monoclonal antibodies and other biopharmaceuticals in goat milk. The platform combines CRISPR-Cas9 gene editing, nuclear transfer, and in vitro fertilization to engineer goats whose milk contains therapeutic proteins at industrial scale; downstream purification yields pharmaceutical-grade products branded as 'BioBodies,' positioned as biosimilars and biobetters with claims of improved glycosylation profiles and materially lower capital and operating costs than mammalian cell-culture bioreactor facilities (traditional plants costing $250–500M in capex).

The company addresses three customer segments: large pharmaceutical companies seeking to lower the cost of monoclonal antibody production, governments and emerging-market countries lacking domestic biopharmaceutical manufacturing capacity, and biotech partners developing oral biologics delivery systems. Bio-Sourcing operates a co-development and co-ownership business model, generating early income through development agreements and long-term revenue through licensing royalties rather than direct product sales. Recent strategic moves include a €1.3 million EUREKA Eurostars-funded joint project with Zerion Pharma (January 2026) to develop an oral formulation of trastuzumab targeting the $4.1 billion global trastuzumab market by 2030, and a strategic alliance with The Tiny Cargo Company (March 2026) to co-develop orally delivered monoclonal antibodies using goat milk-derived exosomes—a category in which no FDA- or EMA-approved products currently exist.

Bio-Sourcing is led by Founder and CEO Dr. Bertrand Mérot, a geneticist and former executive at LFB Biotechnology, GTC Biotherapeutics, and Limagrain Group, supported by a team of 15 scientists including a CSO with dual PhDs from the University of Liège and Oxford. In September 2024 the company secured €12.5 million from the EIC Accelerator (€2.5 million grant plus €10 million equity) to scale goat herds, build an industrial milk processing plant, and fund clinical trials. The company remains at pre-clinical to early-clinical stage with no approved products and Phase I trials for oral trastuzumab targeted around 2030.

Name

Bio-Sourcing

Legal name

Société Anonyme BIO-SOURCING

Website

https://bio-sourcing.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Bio-Sourcing is a Belgian biotech company developing the BioMilk platform, which uses transgenic goats to produce monoclonal antibodies and other biopharmaceuticals in milk for pharmaceutical companies, emerging-market governments, and biotech partners via co-development and licensing agreements.

Ownership category

akta.pro rank

Headquarters

HQ city

Liège

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Co-development and Licensing: Business model based on co-development and co-ownership of results with pharmaceutical partners, generating early income and long-term royalty revenues from biosimilar and biobetter products developed using the BioMilk platform.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Bio-Sourcing develops and operates the proprietary BioMilk™ platform, which produces monoclonal antibodies and other biopharmaceuticals in the milk of transgenic goats. The company co-develops biosimilars and biobetters (including adalimumab and trastuzumab) with pharmaceutical partners, governments, and biotech firms, generating early development income and long-term royalty revenues.

Product overview

Bio-Sourcing offers a single unified technology platform called BioMilk™ for producing biopharmaceuticals. The platform uses transgenic goats as natural bioreactors to express therapeutic proteins (particularly monoclonal antibodies) in milk. The company produces improved biopharmaceuticals called BioBodies, which feature better glycosylation profiles compared to traditional production methods. The platform enables drastic reduction of capital requirements and production costs, particularly for volumes exceeding one ton, while meeting sustainable development goals.

Differentiator

Problem solved

Functional benefit

Brands

• BioMilk: Proprietary technological platform to express proteins of interest in the milk of dedicated animals using transgenic goats as natural bioreactors.

Products and services

• BioMilk™ Platform Proprietary biopharmaceutical production platform that expresses proteins of interest — including fully human monoclonal antibodies — in the milk of transgenic goats created via gene therapy and in vitro fertilization, then purifies them to pharmaceutical grade. Offered to pharmaceutical companies, governments and biotech partners via co-development and licensing arrangements.
• BioBodies (biosimilars and biobetters produced on the BioMilk platform) Improved biopharmaceutical products (biosimilars and biobetters) such as adalimumab and trastuzumab, manufactured via the BioMilk platform with enhanced glycosylation profiles. Co-developed with pharmaceutical partners under co-ownership and long-term royalty arrangements.

Quantifiable outcome

• Production volumes achievable at drastically lower cost for volumes larger than a ton compared to traditional steel bioreactors
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• The Tiny Cargo CompanycoreStrategic or Co-development Partner · 18 March 2026Strategic collaboration to co-develop oral monoclonal antibody therapies using goat-milk extracellular vesicles and exosomes as delivery vehicles. The partnership combines Bio-Sourcing's scalable goat-milk production platform for mAbs and milk EVs with Tiny Cargo's cGMP-ready industrial exosome purification and loading technology. The goal is to create patient-friendly, shelf-stable biologics that eliminate the need for injections and reduce hospital visits. No FDA or EMA-approved oral mAbs currently exist, making this alliance a potential leader in addressing the 'needle barrier'.
• Zerion Pharma A/ScoreStrategic or Co-development Partner · 12 January 2026Joint project awarded €1.3 million EUREKA Eurostars funding to develop an oral formulation of Trastuzumab, a monoclonal antibody used to treat HER2-positive breast cancer. The 36-month project leverages Bio-Sourcing's BioMilk platform and Zerion's Dispersome technology to create an orally deliverable trastuzumab biobetter, with preclinical validation and Phase I studies targeted for around 2030. The global trastuzumab market is estimated at $4.1 billion by 2030.

Scale indicators3 records

Recent moves3 records

Expansion highlights5 records

Direct peers

• Pharming Group: Dutch biotech using transgenic rabbits to produce recombinant C1 esterase inhibitor (Ruconest) for hereditary angioedema. The most direct commercial-stage comparable to Bio-Sourcing's transgenic animal-produced therapeutic platform.
• SAB Biotherapeutics: US biotech using transgenic cattle to produce fully human polyclonal antibodies for infectious disease and oncology. Same core paradigm of transgenic animals as natural bioreactors at industrial scale.
• LFB Group: French plasma/biotech group that acquired GTC Biotherapeutics and markets ATryn, the only FDA-approved transgenic animal-produced therapeutic (made in goat milk). Bio-Sourcing's CEO Dr. Mérot was previously at GTC, making LFB/GTC a direct platform precedent.

Broad incumbents

• Samsung Bioepis: Korean biosimilars joint venture with approved biosimilars of adalimumab (Hadlima), trastuzumab (Ontruzant), and others. Direct end-product competitor to Bio-Sourcing's biosimilar/biobetter pipeline.
• Celltrion: Korean biosimilars leader with approved infliximab (Remsima), rituximab (Truxima), and trastuzumab (Herzuma). Operates in the same target market as Bio-Sourcing's biosimilar ambitions.
• Biocon Biologics: Indian biosimilars leader with multiple approved products (including adalimumab and trastuzumab biosimilars) targeting emerging and developed markets. Competes with Bio-Sourcing for the same biosimilar mAb market.
• Sanofi (Ablynx): Sanofi acquired Ablynx in 2018 for its camelid nanobody platform, which uses transgenic animals (llamas) to produce therapeutic single-domain antibodies. Closest large-pharma example of the transgenic animal-derived antibody model.
• Amgen: Originator of Humira (adalimumab) and now biosimilar competitor with Amjevita. Established incumbent comparator whose commercial scale, pricing leverage, and market access set the bar Bio-Sourcing must undercut.
• Roche: Swiss pharma and originator of Herceptin (trastuzumab) via Genentech. The dominant incumbent whose $4.1B-by-2030 trastuzumab market Bio-Sourcing's biosimilar/biobetter strategy explicitly aims to address.

Regional players

• Argenx: Belgian biotech developing innovative antibody fragment therapeutics (Vyvgart approved for myasthenia gravis). Geographic peer in Belgium's biotech cluster and category peer in differentiated antibody therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio-Sourcing